Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated with Ustekinumab

Trial Profile

Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated with Ustekinumab

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Ustekinumab (Primary) ; Ustekinumab (Primary)
  • Indications Crohn's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms STARDUST
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 26 Jul 2017 Planned End Date changed from 30 Mar 2019 to 28 Jun 2019.
    • 27 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 29 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top